NVO - Novo Nordisk A/S

NYSE - Nasdaq Real-time price. Currency in USD
47.86
-0.82 (-1.68%)
As of 11:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close48.68
Open48.00
Bid47.92 x 1100
Ask47.93 x 600
Day's range47.78 - 48.20
52-week range35.77 - 58.37
Volume461,988
Avg. volume1,545,972
Market cap115.573B
Beta0.82
PE ratio (TTM)18.86
EPS (TTM)2.54
Earnings dateN/A
Forward dividend & yield1.28 (2.61%)
Ex-dividend date2018-03-23
1y target est60.40
Trade prices are not sourced from all markets
  • Analysts’ Recommendations for Novartis on April 17
    Market Realistyesterday

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Alcon
    Market Realistyesterday

    Novartis’s 1Q18 Estimates: Expectations for Alcon

    Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.

  • Novartis’s Innovative Medicines Segment in 1Q18
    Market Realist2 days ago

    Novartis’s Innovative Medicines Segment in 1Q18

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.

  • Novo Nordisk Stock Performance in 1Q18
    Market Realist9 days ago

    Novo Nordisk Stock Performance in 1Q18

    Novo Nordisk (NVO) is a global pharmaceutical company dealing with discovery, development, manufacturing, and commercialization of pharmaceutical products. The company has segregated its business into two segments: Diabetes & Obesity Care and Biopharmaceuticals.

  • Novo Nordisk Obtains Licence for Sickle Cell Disease Program
    Zacks13 days ago

    Novo Nordisk Obtains Licence for Sickle Cell Disease Program

    Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.

  • GlobeNewswire22 days ago

    Market Trends Toward New Normal in Novo Nordisk A/S, Brookfield Asset Management, Dun & Bradstreet, Goldcorp, NorthStar Asset Management Group, and IMAX — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status
    Investor's Business Daily27 days ago

    These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status

    A dozen drugs launching in 2018 from heavy-hitters like Roche, Gilead and J&J are expected to hit blockbuster status over the next five years, an analytics firm predicted Thursday.

  • Novo Nordisk Poised on Strong Pipeline Amid Competition
    Zacks29 days ago

    Novo Nordisk Poised on Strong Pipeline Amid Competition

    Novo Nordisk (NVO) has a strong product pipeline and their potential approval will boost sales of the company.

  • Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
    Zackslast month

    Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns

    Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.

  • Novartis’s Innovative Medicines Business in 4Q17
    Market Realistlast month

    Novartis’s Innovative Medicines Business in 4Q17

    How Novartis Fared in 4Q17

  • How Novartis’s Business Segments Performed in 4Q17
    Market Realistlast month

    How Novartis’s Business Segments Performed in 4Q17

    How Novartis Fared in 4Q17

  • How AstraZeneca’s Other Products Portfolio Performed in 4Q17
    Market Realistlast month

    How AstraZeneca’s Other Products Portfolio Performed in 4Q17

    What's Driving AstraZeneca’s Valuation in March 2018?

  • How AstraZeneca’s Revenues Trended in 4Q17
    Market Realistlast month

    How AstraZeneca’s Revenues Trended in 4Q17

    What's Driving AstraZeneca’s Valuation in March 2018?

  • Novo Nordisk Focuses on Expanding Semaglutide’s Label
    Market Realistlast month

    Novo Nordisk Focuses on Expanding Semaglutide’s Label

    Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.

  • Label Expansion May Boost Xultophy’s Sales in 2018
    Market Realistlast month

    Label Expansion May Boost Xultophy’s Sales in 2018

    What Are Novo Nordisk's Key Growth Drivers for 2018?

  • Saxenda May Continue to Lead in the Diabetes Segment in 2018
    Market Realistlast month

    Saxenda May Continue to Lead in the Diabetes Segment in 2018

    In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64% in local currencies. According to IQVIA, by the end of November 2017, Saxenda accounted for 79%, 86%, 72%, 52%, 47%, 40%, 30%, 19%, 14%, and 6% of the total value of anti-obesity medications sold in the United Arab Emirates, Canada, Denmark, the United States, Italy, Spain, Brazil, Germany, Australia, and Mexico, respectively. In December 2017, Novo Nordisk submitted an application to the FDA seeking an update to Saxenda’s label to include data from the LEADER trial.

  • Xultophy May Prove a Strong Growth Driver for NVO in 2018
    Market Realistlast month

    Xultophy May Prove a Strong Growth Driver for NVO in 2018

    Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017, a 252% YoY (year-over-year) rise on a reported basis and a 255% YoY rise in local currencies. The uptake of Xultophy, a combination of Tresiba and Victoza, was mainly driven by increasing demand in European and North American markets. Xultophy secured approval from the FDA on November 21, 2016, as a once-daily injectable adjunct therapy for type 2 diabetes patients who don’t respond adequately to a daily intake of 50 units of basal insulin or up to 1.8 mg of Victoza (liraglutide).

  • Novo Nordisk Has Developed a Portfolio of New-Generation Insulins
    Market Realistlast month

    Novo Nordisk Has Developed a Portfolio of New-Generation Insulins

    Novo Nordisk (NVO) has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among GPs (general practitioner) and PCPs (primary care physician). Patients suffering from type 1 diabetes are generally treated by endocrinologists, who focus on factors such as low intra-patient glycemic variability, a flat and stable drug profile, fewer hypoglycemia events, patient convenience, and confidence in the product while prescribing drugs. Because GPs and PCPs don’t focus on glycemic variability and hypoglycemia events, Novo Nordisk’s efforts to raise awareness are expected to drive the adoption of Tresiba in the type 2 diabetes patient population.

  • Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits
    Market Realistlast month

    Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits

    Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18. In 4Q17, the company also submitted a supplemental application to the Japanese Ministry of Health, Labour and Welfare for updating Tresiba’s label to reflect hypoglycemia data from the DEVOTE trial. Novo Nordisk is anticipating a readout of the results from its trial comparing Tresiba to insulin glargine U300 in 4Q18.

  • Tresiba Emerged as a Blockbuster Therapy in 2017
    Market Realistlast month

    Tresiba Emerged as a Blockbuster Therapy in 2017

    In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status. The drug has witnessed rapid uptake in markets in which it has par access compared to competing products, such as insulin glargine U100. In the United States, Novo Nordisk managed to attain a 34% share of the total basal insulin market by volume as of January 2018.

  • Will NVO Continue to Lead the Global Insulin Market in 2018?
    Market Realistlast month

    Will NVO Continue to Lead the Global Insulin Market in 2018?

    Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies. The company considers affordability to be the key commercial aspect of its human insulin portfolio, which mainly caters to diabetes patients with lower purchasing power. Novo Nordisk believes that high familiarity owing to long-term presence in the market is a major competitive advantage for its modern insulin portfolio.

  • Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care
    Market Realistlast month

    Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care

    What Are Novo Nordisk's Key Growth Drivers for 2018?

  • Diabetes Care Segment Continues to Drive Growth for NVO in 2018
    Market Realistlast month

    Diabetes Care Segment Continues to Drive Growth for NVO in 2018

    According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes. Of these, 11.2 million patients are estimated to be treated with the company’s human insulin products, 12.5 million with its modern insulin products, 0.9 million with its new-generation insulin products, and the remaining 1.4 million with its glucagon-like peptide 1 (or GLP-1) products.

  • Novo Nordisk Focuses on Raising the Bar in Research in 2018
    Market Realistlast month

    Novo Nordisk Focuses on Raising the Bar in Research in 2018

    In the diabetes care segment, the company is currently focused on developing insulin and glucagon-like peptide 1 (or GLP-1) products, which demonstrate distinct clinical advantages in terms of factors such as the absence of hypoglycemia, reduced comorbidity risk related to cardiovascular events, and weight loss. Novo Nordisk is also evaluating new treatment options with improved delivery mechanisms, such as oral delivery. The above diagram shows the evolution of Novo Nordisk’s insulin and GLP-1 franchises since 1923 and 1986, respectively.

  • Oral Semaglutide May Drive Solid Growth for NVO Going Forward
    Market Realistlast month

    Oral Semaglutide May Drive Solid Growth for NVO Going Forward

    On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1, which evaluated the efficacy of oral semaglutide as a treatment option for type 2 diabetes patients in three different daily dosages: 3 mg, 7 mg, and 14 mg. The investigational therapy demonstrated a statistically significant improvement in blood glucose levels compared to the placebo irrespective of the treatment adherence rates of the patients. In cases where patients adhered to the treatment regimen properly, all oral semaglutide dosages demonstrated a robust drop in both the blood glucose levels and body weights of the patients.